Ambys Medicines has raised $60m in a series A round backed by Takeda and signed a strategic partnership agreement with the corporate worth $80m.
Ambys Medicines, a US-based regenerative medicine developer focused on serious liver diseases, may not be a typical spinout but it is the latest company emerging from venture capital firm Third Rock Ventures’ unique “discover, launch, build” model.
The approach has the firm collaborate with researchers to identify high-potential projects before helping them launch their company with significant series A funding and assisting their growth in the marketplace through a network of pharmaceutical partners.
Third Rock will be familiar to Global…
